Just saw that Metagenomi brought on Eric Bjerkholt to their board—he's the CFO over at Mirum Pharmaceuticals. Dude's got serious credentials, Harvard MBA and a solid track record bouncing around biotech firms. Worked at Chinook before Novartis acquired them, and before that Aimmune got picked up by Nestle. So basically he knows how to scale operations and manage money in this space.

He's joining their Audit and Compensation committees starting late January. The company's pushing hard on gene editing tech—trying to build tools that can fix pretty much any genetic mutation. Bjerkholt seems genuinely excited about it, talking about "innovation and clinical validation" in gene editing. CEO Brian Thomas is hyped too, saying this move helps them advance curative treatments.

Not gonna lie, bringing in someone with Bjerkholt's finance background when you're in early-stage development is a smart play. Though the press release does mention they need "substantial additional funds," which is the usual biotech story. Worth keeping an eye on where this goes, especially if they start filing INDs soon.